Please ensure Javascript is enabled for purposes of website accessibility

Why Shares of Immunovant Are Down Almost 10% This Afternoon

By Jason Hawthorne – Aug 3, 2021 at 3:49PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An analyst note is extending yesterday's sell-off.

What happened

An analyst at Baird downgraded shares of Immunovant (IMVT -0.60%) this morning after its former parent -- Roivant Sciences -- upped its stake in the company with a $200 million investment. The drop adds salt in the wound of the 26% collapse the shares experienced yesterday.

Two businesspeople shaking hands on the steps inside the entrance of a large building.

Image source: Getty Images.

So what

It's not the kind of news that usually tanks shares. But it wasn't the deal shareholders and analysts had expected. Earlier this year, Roivant had said it intended to make an outright purchase of Immunovant. After spinning it out through a special purpose acquisition company (SPAC) in 2019, it appeared Roivant would bring Immunovant's drug for autoimmune conditions back in-house. The same analyst that downgraded the stock today had said a buyout could fetch as much as $26.50 per share. The stock currently trades at $7.

Now what

In the first half of the year, Immunovant had to stop two clinical trials for its drug IMVT-1401 after participants developed high cholesterol levels. It intends to test the drug in other indications, and the investment -- which brings Roivant's stake up to 64% of Immunovant -- will allow that plan to go forward. With the cash infusion, Immunovant's CEO believes the company can get the stalled trials back on track and launch a few others over the next 12 months. 

Immunovant might succeed. Still, it's far from a vote of confidence when a former parent company backs out of a potential acquisition. A cynic might say Roivant is trying to give its former subsidiary a fighting chance while making sure to limit its own exposure.

Jason Hawthorne has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Immunovant, Inc. Stock Quote
Immunovant, Inc.
$13.22 (-0.60%) $0.08

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.